Aug 2026· Journal of Pharmaceutical Innovation· Vol 22· 0 citations· 47 references
TL;DR
This in vitro study suggests that puerarin inhibits NPC cell growth by inducing ferroptosis, providing preliminary phenotypic evidence for further in vivo and mechanistic studies.
Abstract
Nasopharyngeal carcinoma (NPC) is a malignant tumour with a high incidence in Southeast Asia and southern China. Currently, there is a lack of effective targeted therapy strategies for NPC in clinical practice, thus urgently necessitating the development of new treatment methods. Puerarin, the primary active isoflavonoid derived from the traditional Chinese medicine Pueraria lobata, exhibits anti-tumour efficacy in multiple cancer types. However, its function and underlying mechanism in NPC remain unclear. In this study, the human NPC cell lines C666-1 and HK-1 were treated with different concentrations of puerarin either alone or in combination with the ferroptosis inhibitor Fer-1. We employed a series of techniques to investigate the anti-tumour effects, including assessing cell viability, IC50, and apoptosis via CCK-8 and flow cytometry, measuring the levels of glutathione (GSH), malondialdehyde (MDA), and intracellular iron with biochemical detection; detecting reactive oxygen species (ROS) using immunofluorescence, and analyzing the expression of ferroptosis-related proteins GPX4 and SLC7A11 through Western blotting. The findings indicated that puerarin suppressed the viability of C666-1 and HK-1 cells in a dose-dependent manner, with IC50 values of 117.9 µM (24 h) and 85.14 µM (48 h) for C666‑1, and 89.39 µM (24 h) and 50.58 µM (48 h) for HK‑1. Puerarin induced apoptotic cell death, lowered GSH concentrations, and elevated levels of MDA, intracellular iron, and ROS. Meanwhile, puerarin reduced the protein expression of GPX4 and SLC7A11. The Fer-1 reversed all the aforementioned effects of puerarin. This in vitro study suggests that puerarin inhibits NPC cell growth by inducing ferroptosis, providing preliminary phenotypic evidence for further in vivo and mechanistic studies.
Ruscogenin inhibits the malignant progression of nasopharyngeal carcinoma by downregulating KDM1A, thereby promoting apoptosis and ferroptosis and identifies the Rus-KDM1A axis as a promising therapeutic target for NPC treatment.
Bo Zhang· Journal of Visualized Experi...· 0 citations
It is demonstrated that the combination of 4C and talazoparib induces ferroptosis via the SREBP1/FASN axis, providing a promising novel combination therapeutic strategy for the treatment of BC.
Jia Yao, Weifan Wang, Duo Li et al.· Cell Death Discovery· 0 citations
Ovarian cancer (OC) exhibits the highest mortality rate among gynecological cancers, and the development of chemotherapy resistance serves as the primary cause of patient recurrence and death. Natural products hold promise in reversing cisplatin (DDP) resistance. Trigonelline is a natural alkaloid possessing anti-tumor...
Jing Li, Xiao-Xiao Wang, Li-Ya Tu et al.· Toxicon· 0 citations
Colorectal cancer (CRC) frequently develops resistance to 5-fluorouracil (5-FU)-based chemotherapy, which remains a major obstacle to successful treatment. Ginseng-containing Sijunzi Decoction (SJZD), a classical Traditional Chinese Medicine formula, has demonstrated antitumor activity; however, whether and how SJZD en...
Yong Gao, Guo-Qun Chen, Xin-Yu Jiang et al.· The American Journal of Chin...· 0 citations
It is demonstrated that HeA1 exerts potent anti-CRC effects by directly targeting ERO1A to induce ferroptosis through inhibition of the PI3K/AKT/mTOR-SLC7A11/GPX4 axis.
Pei-Pei Li, Lin-Guo Cao, Tao Bi et al.· Cellular Signalling· 0 citations
SF decreased the number of tumor nodules and ameliorated HCC by activating p53 expression, inducing apoptosis, and inhibiting proliferation, oxidative stress, and angiogenesis, and support further translational evaluation of SF as a potential therapeutic agent for HCC.
Kholoud A. Omran, Yomna I. Mahmoud, A. Mahmoud et al.· Experimental oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.